2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1646

Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
Abstract Number: 534

Discordance Between Physician-Stated Remission and 28-Joint Disease Activity Score (DAS28)-Defined Remission in Rheumatoid Arthritis Patients
Abstract Number: 409

Discordance Between Physician, Patient, and Parent Disease Assessment Scores in Juvenile Idiopathic Arthritis
Abstract Number: 2465

Discordance Between Tender and Swollen Joint Count and Patient’s and Evaluator’s Global Assessment May Reduce Likelihood of Remission in Rheumatoid Arthritis
Abstract Number: 897

Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Abstract Number: 1083

Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Abstract Number: 2120

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease
Abstract Number: 1104

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy
Abstract Number: 2704

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis
Abstract Number: 1856

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma
Abstract Number: 1079

Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Abstract Number: 418

Discrepancy in Reported and Actual Rates of Counseling on Teratogenicity and the Need for Contraception When Initiating Mycophenolate in Women of Childbearing Age
Abstract Number: 746

Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Abstract Number: 2719

Discriminating Value of Calprotectin in Disease Activity and Progression of Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
Abstract Number: 404

Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].